Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Raloxifene to Induce Ovulation in Polycystic Ovarian Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Women aged 18 to 36~2. BMI \> 19 \& \< 40~3. PCOS diagnosis as evidenced by:~Oligo- and/or anovulation (\< 6 cycles per year) and one of the following:~* Clinical and/or biochemical signs of hyperandrogenism~* Polycystic ovaries and exclusion of other aetiologies (congenital adrenal hyperplasias, androgen-secreting tumors, Cushing's syndrome)~Exclusion Criteria:~1. Use of ovulation induction agents within the past 6 months~2. Positive pregnancy test before taking study medications~3. History or current thromboembolic disorder~4. Coronary artery disease such as heart attack or stroke~5. Tobacco use or history within the past 6 months~6. History of pelvic inflammatory disease and tubal factor infertility~7. Congenital adrenal hyperplasia~8. Diabetes Mellitus~   * Any subject on Metformin must wash out for 30 days prior to screening~9. History of endometriosis~10. Known male factor infertility

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 36 Years
- Healthy Volunteers: f

Study Arms:
- Raloxifene (Type: EXPERIMENTAL): 3 cycles of 120mg/day of Evista (raloxifene) on days 3 to 7
- Clomiphene (Type: ACTIVE_COMPARATOR): 3 cycles of 100mg/day of Clomid (clomiphene citrate) on days 3 to 7

Based on this trial design, predict the completion outcome and termination type (if applicable).